Tio life science-projekt får miljonanslag – ny utlysning öppnar

En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.

Security flaw in Swedish breast cancer screening software – woman passed away

A lack of safeguard in Sectra's software led to a woman with breast cancer receiving an incorrect diagnosis. She later passed away. The software is used in 20 o...

Introduction of ZEISS Imaging Systems for Super-Resolution

Webinar recording about the ZEISS Lattice SIM technology.

She is CSL Behring's new Nordic General Manager

Since the beginning of january, Helena Bragd is the new Nordic General Manager for the biotech company CSL Behring and CEO of CSL Behring AB.

Här är nyheterna som klickades mest i sommar

Ny vd hos Novo Nordisk, globala nedskärningar hos läkemedelsjättar och mångmiljonböter för ett omtalat life science-bolag. Det är några av de mest lästa nyheter...

BioArctic moves forward with its candidate for Parkinson’s

BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.

LINK Medical recruits Swedish CEO

The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.

Mastering Urine Microscopy: Techniques for Accurate Disease Detection

Live Webinar on September 25, 2024.

Viktor Hrvota dubblar vd-skapet – tar över Umecrine Cognition

Umecrine Cognition har utsett Viktor Drvota till ny vd efter avgående Anders Karlsson.

Moderna develops mRNA vaccine against norovirus

A highly anticipated vaccine is in late clinical evaluation and could be ready for approval within a couple of years. The target is the norovirus, often called ...

New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...

AstraZeneca to use American AI platform for cancer trials

In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.

FDA’s Top Vaccine Official resigns – Issues sharp criticism of Kennedy

FDA’s Top Vaccine Official is leaving his post while simultaneously criticizing the country’s health secretary for allowing “misinformation and lies” to influen...

CTC Clinical Trial Consultants AB

Quiet, fast, inexpensive: mass flow controller for life sciences

Whether in portable oxygen system devices or in bioreactors, the new proportional flow control valve VEMD from Festo provides extremely high control dynamics an...

Pharma Outsourcing – Find the right partner

Meet us at Control 2025

Innovations that drive efficiency.

Automated nitrogen analysis reduces costs per sample

N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo

USA:s regering skrotar vaccinavtal med Moderna

Trumpadministrationen har avbrutit ett kontrakt som tilldelats Moderna för den sena utvecklingsfasen av ett fågelinfluensavaccin för människor, samt rätten att ...

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

Index rekommenderas avsluta studie: ”Överraskande och nedslående”

En oberoende kommitté rekommenderar Index Pharmaceuticals att avbryta sin fas III-studie med läkemedelskandidaten Cobitolimod, som prövas som behandling mot ulc...

Scientific Solutions

Svensk obesitaskandidat visade lovande resultat – ”Kan få stor betydelse”

Tabletten ska främja viktminskning utan att påverka aptit eller muskelmassa. Resultaten är lovande, enligt en klinisk fas I-studie från Karolinska institutet oc...

Lilly recruits top Swedish researcher in Alzheimer´s

One of Sweden's leading Alzheimer's researchers, Oskar Hansson, has been recruited by pharma giant Eli Lilly and will be moving to the USA.